Urology
<ѻý class="page-description">News, opinions and meeting coverage in urology.— Patients with complete response can have long treatment-free interval, study suggests
Latest in Urology
Other IKCS news: closer look at belzutifan safety, challenges of triplet therapies for RCC
Possible guidance for use of adjuvant immunotherapy in high-risk, non-metastatic disease
Better OS, PFS, response rate, but newer combination strategies not included
VA analysis finds men with limited life expectancy still getting aggressive treatment
Better OS, PFS, response rate, but newer combination strategies not included
VA analysis finds men with limited life expectancy still getting aggressive treatment
More in Urology
More IKCS news: Long-term survival benefit with nivolumab/ipilimumab, disease-slowing surgery
Low rate of recurrence with surgery or nonsurgical options, but data can inform decisions
Confirmed responses in one-fourth to one-third of patients with refractory disease
And nearly half of responders to enfortumab vedotin plus pembrolizumab remained in remission
Researchers say inadequate understanding of risks may lead patients to regret treatment decisions
Health news and commentary gathered by ѻý staff
Meta-analysis finds one most effective option to prevent symptomatic episodes
Study also raises question of antibiotic prophylaxis in kids with common congenital anomaly
New oral antibiotic gets a nod for uncomplicated urinary tract infections
Only 4% reported regret after receiving puberty blockers, gender-affirming hormones
In confirmatory trial, antibody-drug conjugate failed to improve OS versus chemotherapy
Odds of undetectable PSA at 48 weeks doubled with addition of Pluvicto
Low rates of toxicity and salvage cystectomy, with 2-year survival similar to surgery
